{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"0.97","value":"0.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Proportion of patients who are still alive at 1 year after registration.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive bortezomib subcutaneously on days 1, 8, and 15; liposomal doxorubicin intravenously (IV) over 1 hour on day 4; oral dexamethasone on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.\n\nliposomal doxorubicin: Given IV\n\nbortezomib: Given subcutaneously.\n\ndexamethasone: Given orally\n\ncyclophosphamide: Given IV","id":"OG000","title":"Treatment (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"All eligible and treated patients are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed at 1 year","title":"One-year Survival in Patients Treated With This Regimen.","type":"PRIMARY","unitOfMeasure":"Proportion of patients"}